Want to see BGMS full AI Analyst Report?
Bio Green Med Solution (BGMS) AI Stock Analysis
Bio Green Med Solution
(NASDAQ:BGMS)
The score is primarily constrained by weak fundamentals—large ongoing losses and negative free cash flow—despite improving revenue and a low-debt balance sheet. Technicals are neutral-to-soft with modestly negative momentum. Corporate events add uncertainty due to potentially extreme dilution from the proposed business combination, offsetting some of the benefit from improved quarterly results.
Bio Green Med Solution (BGMS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.97M
- Dividend Yield
- ―
- Average Volume (3M)
- 75.67K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 0.84
- Revenue Growth
- 18510.00%
- EPS Growth
- 98.80%
- Country
- US
- Employees
- 12
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Medical - Pharmaceuticals
Bio Green Med Solution Business Overview & Revenue Model
Company Description
Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitter...
Bio Green Med Solution Earnings Call Summary
The earnings call reflects a positive outlook with significant progress in the clinical development of fadra and a strong financial position, despite some challenges in R&D tax credits and increased expenses for topogezotitib.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Cyclacel Q2 2024 earnings call, the company provided key updates on their precision medicine strategy, particularly focusing on fadra, an oral CDK2/9 inhibitor. Recruitment is progressing well in the 065-101 Phase II proof-of-concept study, with an enriched cohort targeting patients with CDKN2A and CDK NIB chromosomal abnormalities. Initial clinical activity results are expected in Q4 2024. Financially, Cyclacel reported cash equivalents of $6 million as of June 2024, with net cash used in operating activities amounting to $3.6 million for the first half of the year, indicating a decrease from $8.2 million in the same period of 2023. Research and development expenses for the quarter were $2 million, a reduction from $4.7 million in Q2 2023, with specific R&D expenses for fadra at $1.5 million, down from $3 million the previous year. The company anticipates that current cash resources will cover planned programs into the fourth quarter of 2024.
Bio Green Med Solution Financial Statement Overview
Summary
Revenue is growing (TTM ~$1.86M, ~22% YoY) and the balance sheet shows low leverage with essentially no debt and positive equity (~$7.16M). However, profitability and cash sustainability remain very weak with deeply negative operating/net margins and continued negative operating and free cash flow (TTM OCF and FCF about -$1.10M).
Income Statement
18Very NegativeBalance Sheet
64PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.86M | 747.00K | 43.00K | 420.00K | 0 | 0 |
| Gross Profit | 360.00K | 138.00K | 43.00K | 420.00K | -32.00K | -43.00K |
| EBITDA | -2.73M | -8.42M | -12.00M | -25.42M | -27.62M | -22.35M |
| Net Income | -2.20M | -3.00M | -11.21M | -22.55M | -21.20M | -18.46M |
Balance Sheet | ||||||
| Total Assets | 7.85M | 8.19M | 4.09M | 8.80M | 28.05M | 43.14M |
| Cash, Cash Equivalents and Short-Term Investments | 3.79M | 3.50M | 3.14M | 3.38M | 18.34M | 36.56M |
| Total Debt | 0 | 2,000 | 0 | 37.00K | 106.00K | 30.00K |
| Total Liabilities | 694.00K | 1.34M | 6.27M | 8.20M | 7.62M | 5.44M |
| Stockholders Equity | 7.16M | 6.84M | -2.17M | 607.00K | 20.43M | 37.69M |
Cash Flow | ||||||
| Free Cash Flow | -1.10M | -4.77M | -7.99M | -16.12M | -20.83M | -18.57M |
| Operating Cash Flow | -1.10M | -4.77M | -7.99M | -16.11M | -20.83M | -18.54M |
| Investing Cash Flow | -1,000 | 0 | 0 | -6,000 | -7,000 | -27.00K |
| Financing Cash Flow | 616.00K | 5.26M | 7.82M | 848.00K | 3.00M | 21.74M |
Bio Green Med Solution Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BGMS, the sentiment is Negative. The current price of 0.92 is above the 20-day moving average (MA) of 0.91, above the 50-day MA of 0.90, and below the 200-day MA of 0.97, indicating a bearish trend. The MACD of 0.00 indicates Positive momentum. The RSI at 49.03 is Neutral, neither overbought nor oversold. The STOCH value of 29.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BGMS.
Bio Green Med Solution Risk Analysis
Bio Green Med Solution disclosed 63 risk factors in its most recent earnings report. Bio Green Med Solution reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksBio Green Med Solution Peers Comparison
Overall Rating
NEUP48Neutral- BGMS46Neutral
BDRX44Neutral
BJDX44Neutral
RNTX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| NEUP | 48Neutral | $16.50M | -0.42 | -77.03% | ― | ― | ― |
| BGMS | 46Neutral | $5.96M | -0.25 | -31.60% | ― | 18510.00% | 98.80% |
| BDRX | 44Neutral | $1.80M | -64.03 | -42.42% | ― | ― | 97.97% |
| BJDX | 44Neutral | $2.49M | -0.05 | -125.01% | ― | ― | 93.91% |
| RNTX | 40Underperform | $57.80M | -0.37 | -234.45% | ― | ― | 36.23% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BGMS | Bio Green Med Solution, Inc. | 0.90 | -0.69 | -43.40% | |
| BDRX | Biodexa Pharmaceuticals Plc | 3.43 | -212.57 | -98.41% | |
| RNTX | Rein Therapeutics, Inc | 0.67 | -0.75 | -52.82% | |
| BJDX | Bluejay Diagnostics, Inc. | 0.56 | -6.60 | -92.23% | |
| NEUP | Neuphoria Therapeutics Inc. | 3.05 | -1.17 | -27.73% |
Bio Green Med Solution Corporate Events
Bio Green Med Solution Declares Quarterly Preferred Dividend
PositiveOn October 15, 2026, Bio Green Med Solution, Inc.’s board declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend was scheduled to be paid on November 1, 2026, to preferred sharehol...
Bio Green Med Solution Reports Improved Q2 2026 Results
PositiveBio Green Med Solution Inc., a Malaysia-headquartered Nasdaq-listed company, has transitioned from its former biopharmaceutical focus to a core business in fire safety protection and equipment distribution since acquiring Fitters Sdn. Bhd. in Septemb...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026